Tables
TABLE 1 ANTI-OBESITY DRUGS MARKET REVENUE BY REGIONS' 2016-2023 ($MILLION) 32
TABLE 2 F. HOFFMANN-LA ROCHE: OFFERINGS 43
TABLE 3 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 43
TABLE 4 GLAXOSMITHKLINE PLC: OFFERINGS 48
TABLE 5 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 48
TABLE 6 VIVUS' INC.: OFFERINGS 54
TABLE 7 VIVUS' INC.: RECENT DEVELOPMENTS 54
TABLE 8 OREXIGEN THERAPEUTICS' INC.: OFFERINGS 57
TABLE 9 OREXIGEN THERAPEUTICS' INC.: RECENT DEVELOPMENTS 57
TABLE 10 EISAI CO.' LTD.: OFFERINGS 60
TABLE 11 EISAI CO.' LTD.: RECENT DEVELOPMENTS 60
TABLE 12 PFIZER: RECENT DEVELOPMENTS 63
TABLE 13 NOVO NORDISK: OVERVIEW 64
TABLE 14 NOVO NORDISK: RECENT DEVELOPMENTS 65
TABLE 15 BOEHRINGER INGELHEIM GMBH: OVERVIEW 65
TABLE 16 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 66
TABLE 17 RHYTHM PHARMACEUTICALS' INC.: OVERVIEW 66
TABLE 18 RHYTHM PHARMACEUTICALS' INC.: RECENT DEVELOPMENTS 66
TABLE 19 ZAFGEN: OVERVIEW 67
TABLE 20 NORGINE B.V.: OVERVIEW 67
TABLE 21 MERCK & CO.: OVERVIEW 68
TABLE 22 MERCK & CO.: RECENT DEVELOPMENTS 68
TABLE 23 TAKEDA PHARMACEUTICAL CO.' LTD.: OVERVIEW 69
TABLE 24 TAKEDA PHARMACEUTICAL CO.' LTD.: RECENT DEVELOPMENTS 69
?

LIST OF FIGURE

Charts

CHART 1 RESEARCH METHODOLOGY OF GLOBAL ANTI-OBESITY DRUGS MARKET 11
CHART 2 GLOBAL ANTI-OBESITY DRUGS MARKET REVENUE' 2016-2023 ($MILLION) 14
CHART 3 OBESITY-RELATED COST BY COUNTRY AS A PERCENTAGE OF TOTAL HEALTHCARE SPENDING (%) 17
CHART 4 SEGMENTATION OF GLOBAL ANTI-OBESITY DRUGS MARKET 17
CHART 5 PORTER 5 FORCES OF ANTI-OBESITY DRUGS MARKET 18
CHART 6 PEST ANALYSIS OF ANTI-OBESITY DRUGS MARKET 19
CHART 7 MARKET EVOLUTION 20
CHART 8 MARKET DYNAMICS - DRO ANALYSIS 21
CHART 9 DRO - IMPACT ANALYSIS OF GLOBAL ANTI-OBESITY DRUGS MARKET 24
CHART 10 KEY STAKEHOLDERS 25
CHART 11 ANTI-OBESITY DRUGS MARKET REVENUE BY TYPES SEGMENTATION' 2016 ($MILLION) 26
CHART 12 ANTI-OBESITY DRUGS MARKET REVENUE BY TYPES SEGMENTATION' 2016 ($MILLION) 29
CHART 13 PRESCRIPTION DRUGS (RX) MARKET REVENUE BY TYPES SEGMENTATION' 2016-2023 ($MILLION) 30
CHART 14 OTC DRUGS MARKET REVENUE BY TYPES SEGMENTATION' 2016-2023 ($MILLION) 30
CHART 15 ANTI-OBESITY DRUGS MARKET SHARE BY REGIONAL SEGMENTATION' 2016 (%) 31
CHART 16 ANTI-OBESITY DRUGS MARKET SHARE BY REGIONAL SEGMENTATION' 2023 (%) 32
CHART 17 ANTI-OBESITY DRUGS MARKET REVENUE IN NORTH AMERICA' 2017-2023 ($MILLION) 33
CHART 18 EUROPEAN COUNTRIES' OBESITY RATE IN 2014 35
CHART 19 ANTI-OBESITY DRUGS MARKET REVENUE IN EUROPE' 2016-2023 ($MILLION) 35
CHART 20 ANTI-OBESITY DRUGS MARKET REVENUE IN ASIA PACIFIC' 2016-2023 ($MILLION) 37
CHART 21 ANTI-OBESITY DRUGS MARKET REVENUE IN REST OF THE WORLD' 2016-2023 ($MILLION) 38
CHART 22 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT 44
CHART 23 F. HOFFMANN-LA ROCHE: BUSINESS UNITS 45
CHART 24 F. HOFFMANN-LA ROCHE: GEOGRAPHIC REVENUE 46
CHART 25 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS 47
CHART 26 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT 49
CHART 27 GLAXOSMITHKLINE PLC: BUSINESS UNITS 50
CHART 28 GLAXOSMITHKLINE PLC: GEOGRAPHIC REVENUE 51
CHART 29 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 52
CHART 30 VIVUS' INC.: OVERVIEW SNAPSHOT 54
CHART 31 VIVUS' INC.: SWOT ANALYSIS 55
CHART 32 OREXIGEN THERAPEUTICS' INC.: OVERVIEW SNAPSHOT 58
CHART 33 OREXIGEN THERAPEUTICS' INC.: SWOT ANALYSIS 59
CHART 34 EISAI CO.' LTD.: OVERVIEW SNAPSHOT 60
CHART 35 EISAI CO.' LTD.: GEOGRAPHIC REVENUE 61
CHART 36 EISAI CO.' LTD.: SWOT ANALYSIS 61